Willard Dere

Willard H.
Dere currently works at Metagenomi, Inc., as Chairman from 2025, BioMarin Pharmaceutical, Inc., as Independent Director from 2016, Mersana Therapeutics, Inc., as Independent Director from 2018, Seres Therapeutics, Inc., as Independent Director from 2017, Peel Therapeutics, Inc., as Director, and Angitia Biopharmaceuticals Guangzhou Ltd., as Chief Medical Officer from 2023.
Dr. Dere also formerly worked at Radius Health, Inc., as Independent Director from 2014 to 2022, OCERA Therapeutics LLC, as Independent Director from 2016 to 2017, The University of Utah Health Sciences Center, as Professor & Executive Director-Personalized Health from 2014 to 2022, Metagenomi Technologies LLC, as Director, Eli Lilly & Co., as Vice President-Endocrine & Bone from 1989 to 2003, Clinical & Translational Science Institute, as Associate Vice President-Research, The Indiana University School of Medicine, as Associate Professor from 1999 to 2009, Center for Genomic Medicine Massachusetts General Hospital, as Principal, and Amgen, Inc., as International Chief Medical Officer from 2007 to 2014.
Dr. Dere received his undergraduate degree in 1977 and doctorate degree in 1980 from the University of California, Davis.